edoc
Coronavirus (COVID-19) [Webpage].
United States. Substance Abuse and Mental Health Services Administration.
Federal Publication/Policy
Resource Listing
1 HTML page
Public Domain
Published: Constantly updated
Substance Abuse and Mental Health Services Administration (SAMHSA)
5600 Fishers Lane
Rockville, MD 20857
Tel: (877) 726-4727
Fax: (240) 276-2010
info@samhsa.gov
Available From:http://www.samhsa.gov/
View: https://www.samhsa.gov/coronavirus
This website provides links to substance abuse and mental health services resources designed to be helpful during the COVID-19 pandemic. A list of Substance Abuse and Mental Health Services Association (SAMHSA) resources is included that addresses emergency grants to address mental and substance use disorders during COVID-19, information for SAMHSA discretionary grant recipients, COVID-19 public health emergency responses and 42 CFR Part 2 guidance, disaster planning for behavioral health treatment programs, considerations for the care and treatment of mental and substance use disorders during the COVID-19 epidemic, considerations for crisis centers and clinicians managing the treatment of alcohol or benzodiazepine withdrawal during the COVID-19 epidemic, considerations for outpatient mental and substance use disorder treatment settings, COVID-19 interim considerations for State psychiatric hospitals, virtual recovery resources, tips for social distancing, quarantine, and isolation during an infectious disease outbreak, the disaster distress hotline, and telework and DFWP drug testing during COVID-19. Additional links are provided to resources for opioid treatment programs, additional federal guidance, and government websites that provide updated information on COVID-19.
Keywords:
COVID-19; COMMUNICABLE DISEASES; DISASTER PLANNING; REMOTE SERVICE DELIVERY; DRUG TREATMENT PROGRAMS; SUBSTANCE ABUSE TREATMENT; MENTAL HEALTH PROGRAMS; MENTAL HEALTH SERVICES; PSYCHIATRIC HOSPITALS; DRUG WITHDRAWAL SYMPTOMS; OPIOID ADDICTION; FEDERAL PROGRAMS; GRANTS; GUIDELINES; AGENCY PRACTICE; COVID-19 CB